(Reuters) -Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients in the U.S. to access Ozempic for $499 per month.

The company said this was part of its ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines.

It said the offer would be available through multiple platforms, including through telehealth service GoodRx ( GDRX ).